Journal
CURRENT INFECTIOUS DISEASE REPORTS
Volume 21, Issue 9, Pages -Publisher
SPRINGER
DOI: 10.1007/s11908-019-0687-4
Keywords
Trichomonas vaginalis; Trichomoniasis; Metronidazole; Tinidazole; Resistant trichomoniasis; Metronidazole resistance
Categories
Ask authors/readers for more resources
Purpose of Review Trichomonas vaginalis is the most prevalent sexually transmitted parasite in the USA; resistant infection is emerging. New drug therapies and dosing regimens of standard therapies are being studied to treat resistant infection. Recent Findings Diagnosis of trichomoniasis has become more sensitive, specific, and widely available with the advent of nucleic acid amplification tests (NAATs). Women with resistant trichomoniasis should be treated with high-dose regimens of metronidazole or tinidazole. Alternative treatment options have been described, and there has been some success particularly with high-dose tinidazole/intravaginal paromomycin cream combination, intravaginal boric acid, and intravaginal metronidazole/miconazole. Resistant trichomoniasis is a growing public health concern with implications for long-term health consequences. More data are needed to further evaluate mechanisms by which resistance occurs as well as promising therapies for those affected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available